-
ASCO International Perspectives丨Dr. Areej El-Jawahri: Collaborative Palliative Care Optimizes End-of-Life Strategies for AML and MDS Patients
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, a multicenter randomized clinical trial was presented, focusing on a collaborative palliative care and oncology model for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) receiving non-intensive treatment (Abstract LBA6508). Dr. Areej El-Jawahri from Massachusetts General Hospital shared her professional insights…
-
ASCO 2024丨Professor Meisel Discusses I-SPY2.2 Study on TROP-2 ADC Neoadjuvant Therapy
With advancements in medical research and technology, new therapies for complex diseases like breast cancer are continually emerging. Dato-DXd, a novel antibody-drug conjugate (ADC), shows potential in the treatment of breast cancer. The I-SPY2.2 trial, presented at ASCO 2024, utilizes an innovative trial design to demonstrate the efficacy of Dato-DXd as a monotherapy in HR-HER2-negative…
-
ASCO China Voice | Professor Min Yan: Utidelone Combined with Bevacizumab is Safe and Effective for Treating Brain Metastases in HER2-Negative Breast
Brain metastasis from breast cancer has a high incidence, second only to lung cancer . Previous studies have shown that patients with brain metastases have poorer survival compared to those without brain metastases, with HER2-negative breast cancer brain metastasis patients having an even worse prognosis . Due to the blood-brain barrier (BBB), many drug treatments…
-
ASCO Researchers Speak丨Professor Jin Li: Utidelone Becomes a New First-Line Combination Therapy Option for Advanced Gastric Cancer
At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, a multi-center study led by Professor Jin Li from Shanghai GaoBo Oncology Hospital, China Pharmaceutical University, reported that utidelone demonstrated significant anti-tumor activity in various pre-treated advanced solid tumors, particularly in first-line treatment of advanced gastric cancer. Oncology Frontier invited Professor Jin Li to…
-
EASL China Voice丨Professor Jian Gao Fan: Selective THR-β Agonist ASC41 Significantly Reduces Liver Fat and ALT Levels in MASH Patients After 12 Weeks
From June 5 to 8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. This major event brought together over 7,000 professionals, including clinicians, researchers, healthcare workers, patient representatives, and industry experts. During the conference, Professor Jian Gao Fan from the Xinhua Hospital Affiliated to Shanghai…
-
EASL Featured New Voices丨Functional Cure of Chronic Hepatitis B: A Promising Journey
Chronic hepatitis B (CHB) remains a significant global health issue. At this year’s European Association for the Study of the Liver (EASL) Annual Meeting, the functional cure of CHB emerged as a focal point of research. “Hepatology Digest” had the privilege of speaking with Mr. Graham Griffiths, Chief Brand Officer at Barinthus Biotherapeutics, to gain…
-
EASL Voice of China丨Professor Yu Chen: Promising Prospects for HYX1 Liver Stem Cells in Treating Acute Liver Failure by Inhibiting Ferroptosis through Exosomes
Acute liver failure (ALF) is a severe liver injury caused by factors such as drugs, viruses, and ischemia-reperfusion injury, leading to massive hepatocyte apoptosis, necrosis, and potentially irreversible liver damage. The condition progresses rapidly, with high short-term mortality rates and poor prognosis, while medical treatment options are limited. Although liver transplantation is an effective strategy…
-
EASL Voice of China丨Professor Jian Sun: Correlation Between Serum HBV RNA and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) is a global public health issue, with hepatocellular carcinoma (HCC) being one of its most severe complications. Traditional viral markers have limited efficacy in predicting HCC risk, highlighting the need for new viral predictive indicators. On June 5, 2024, at the European Association for the Study of the Liver (EASL) annual…
Connecting Medical Expertise through Media